Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms Post author: Post published:November 22, 2023 Post category:uncategorized Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19. You Might Also Like AR3-based optogenetic strategy shows high efficacy in inducing apoptosis and antitumor effects December 2, 2025 Researchers successfully perform coronary artery bypass without cutting the chest wall January 6, 2026 Study provides new insights into the genetic underpinnings of pediatric cancers January 2, 2025
AR3-based optogenetic strategy shows high efficacy in inducing apoptosis and antitumor effects December 2, 2025
Researchers successfully perform coronary artery bypass without cutting the chest wall January 6, 2026